4.7 Article

DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery

期刊

GENOMICS PROTEOMICS & BIOINFORMATICS
卷 18, 期 2, 页码 104-119

出版社

ELSEVIER
DOI: 10.1016/j.gpb.2019.11.008

关键词

Data-independent acquisition; Parallel reaction monitoring; Spectral library; Prostate cancer; Diffuse large B cell lymphoma

资金

  1. National Natural Science Foundation of China [81972492]
  2. National Science Fund for Young Scholars [21904107]
  3. Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars [LR19C050001]
  4. Hangzhou Agriculture and Society Advancement Program [20190101A04]
  5. Westlake Startup Grant
  6. National Cancer Centre Singapore
  7. National Key R&D Program of China [2016YFC0901704]
  8. Zhejiang Innovation Discipline Project of Laboratory Animal Genetic Engineering [201510]
  9. Netherlands Cancer Society [NKI 2014-6651]
  10. Netherlands Organization for Scientific Research (NWO)-Middelgroot [91116017]
  11. Singapore General Hospital, Singapore

向作者/读者索取更多资源

To address the increasing need for detecting and validating protein biomarkers in clinical specimens, mass spectrometry (MS)-based targeted proteomic techniques, including the selected reaction monitoring (SRM), parallel reaction monitoring (PRM), and massively parallel dataindependent acquisition (DIA), have been developed. For optimal performance, they require the fragment ion spectra of targeted peptides as prior knowledge. In this report, we describe a MS pipeline and spectral resource to support targeted proteomics studies for human tissue samples. To build the spectral resource, we integrated common open-source MS computational tools to assemble a freely accessible computational workflow based on Docker. We then applied the workflow to generate DPHL, a comprehensive DIA pan-human library, from 1096 data-dependent acquisition (DDA) MS raw files for 16 types of cancer samples. This extensive spectral resource was then applied to a proteomic study of 17 prostate cancer (PCa) patients. Thereafter, PRM validation was applied to a larger study of 57 PCa patients and the differential expression of three proteins in prostate tumor was validated. As a second application, the DPHL spectral resource was applied to a study consisting of plasma samples from 19 diffuse large B cell lymphoma (DLBCL) patients and 18 healthy control subjects. Differentially expressed proteins between DLBCL patients and healthy control subjects were detected by DIA-MS and confirmed by PRM. These data demonstrate that the DPHL supports DIA and PRM MS pipelines for robust protein biomarker discovery. DPHL is freely accessible at https://www.iprox.org/page/project.html?id=IPX0001400000.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据